Quick Answer
ATOSSA THERAPEUTICS, INC. reported Diluted EPS of $4.04 per share (loss) for fiscal year 2025.
ATOSSA THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.04 | -32.9% |
| 2024 | -$3.04 | -1166.7% |
| 2023 | -$0.24 | -14.3% |
| 2022 | -$0.21 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.07 | -16.7% | +0.0% |
| June 30, 2025 | -$0.07 | -40.0% | -40.0% |
| March 31, 2025 | -$0.05 | +0.0% | +16.7% |
| September 30, 2024 | -$0.06 | -20.0% | -20.0% |
| June 30, 2024 | -$0.05 | +37.5% | +0.0% |
| March 31, 2024 | -$0.05 | +0.0% | +0.0% |
| September 30, 2023 | -$0.05 | — | +37.5% |
| June 30, 2023 | -$0.08 | — | -60.0% |
- ATOSSA THERAPEUTICS, INC. showed a decrease of -32.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, ATOSSA THERAPEUTICS, INC.’s diluted eps has declined by 1823.8% (from $0.21 per share (loss) to $4.04 per share (loss)).
- The most recent figure is from ATOSSA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: